Compare TRNO & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRNO | BIO |
|---|---|---|
| Founded | 2009 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.9B |
| IPO Year | 2009 | N/A |
| Metric | TRNO | BIO |
|---|---|---|
| Price | $65.87 | $312.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $67.83 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 603.5K | 471.8K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 103.65 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $476,383,000.00 | N/A |
| Revenue This Year | $8.42 | $2.74 |
| Revenue Next Year | $9.10 | $3.20 |
| P/E Ratio | $100.91 | ★ $9.72 |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $211.43 |
| 52 Week High | $67.55 | $343.12 |
| Indicator | TRNO | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 68.29 |
| Support Level | $64.01 | $293.88 |
| Resistance Level | $67.03 | $330.54 |
| Average True Range (ATR) | 1.13 | 9.86 |
| MACD | -0.00 | 6.66 |
| Stochastic Oscillator | 52.52 | 90.63 |
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.